<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150123</url>
  </required_header>
  <id_info>
    <org_study_id>V98_06</org_study_id>
    <nct_id>NCT01150123</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women</brief_title>
  <official_title>A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Group 1</measure>
    <time_frame>Day 1 and Day 61</time_frame>
    <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL as determined by ELISA at day 61 across cohorts 1 and 2 for potential use in pregnant women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 61</measure>
    <time_frame>Day 1 and Day 61</time_frame>
    <description>Serotype-specific (Ia, Ib &amp; III) group B streptococcus (GBS) IgG antibody levels in healthy subjects for potential use in pregnant woman was assessed in terms of Geometric Mean Concentrations (GMCs) at Day 61 in cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype</measure>
    <time_frame>Day 61/Day 1</time_frame>
    <description>Geometric mean ratios (GMRs) relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels measured at Day 61 for subjects across cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Groups 1 &amp; 2</measure>
    <time_frame>Day 1 and Day 361</time_frame>
    <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL at day 361 across all the cohorts for potential use in non-pregnant women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 361</measure>
    <time_frame>Day 1 and Day 361</time_frame>
    <description>Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant woman was assessed in terms of GMCs at Day 361 across all cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype at Day 361</measure>
    <time_frame>Day 1 and day 361</time_frame>
    <description>GMRs relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant women, measured at Day 361 across all cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Adverse Events (AEs) After Receiving the GBS Trivalent Vaccine in Enrollment Group 1</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving trivalent GBS vaccine from day 1 to day 7 for subjects across cohorts 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited AEs After Receiving the GBS Trivalent Vaccine in Enrollment Group 2</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving GBS vaccine from day 1 to day 7 for subjects in cohorts 3 and 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 1</measure>
    <time_frame>Day 1 through Day 721</time_frame>
    <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 2</measure>
    <time_frame>Day 1 through Day 721</time_frame>
    <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 3 and 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype for Subjects in Enrollment Group 1</measure>
    <time_frame>Day 1 and Day 721</time_frame>
    <description>The persistence of Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody response was assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohorts 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype in Subjects in Enrollment Group 2</measure>
    <time_frame>Day 1 and Day 721</time_frame>
    <description>The persistence of Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody response assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohort 3 and 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 1</measure>
    <time_frame>Day 1 and Day 721</time_frame>
    <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across all cohorts 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 2</measure>
    <time_frame>Day 1 and Day 721</time_frame>
    <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across cohorts 3 and 4.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Group B Streptococcus</condition>
  <arm_group>
    <arm_group_label>5 µg_No Adj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg_No Adj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 µg_Alum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg_Alum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 µg_MF59-H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg_MF59-H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 µg_MF59-F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg_MF59-F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 2 injections of placebo administered 1 month apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus (GBS) vaccine- low dose</intervention_name>
    <arm_group_label>5 µg_No Adj</arm_group_label>
    <arm_group_label>5 µg_Alum</arm_group_label>
    <arm_group_label>5 µg_MF59-H</arm_group_label>
    <arm_group_label>5 µg_MF59-F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group B streptococcus (GBS) vaccine- High dose</intervention_name>
    <arm_group_label>20 µg_No Adj</arm_group_label>
    <arm_group_label>20 µg_Alum</arm_group_label>
    <arm_group_label>20 µg_MF59-H</arm_group_label>
    <arm_group_label>20 µg_MF59-F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo- Saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy females 18-40 years of age inclusive.

        Exclusion Criteria:

          -  Individuals who are pregnant or nursing.

          -  Individuals who have had a previous immunization with a vaccine containing
             streptococcus antigens or any vaccine within 30 days of enrollment through 30 days of
             study completion.

          -  Individuals with a history of severe allergic reactions after previous vaccination

          -  Individuals with designated blood tests that are not within normal range
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <results_first_submitted>April 3, 2014</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Group B streptococcus</keyword>
  <keyword>GBS</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Group B streptococcus (GBS) disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at one center in Belgium</recruitment_details>
      <pre_assignment_details>Group1: 5 µg-1Inj-No Adj, 5 µg-2Inj-No Adj, 20 µg-1Inj-No Adj, 20 µg-2Inj-No Adj (Cohort 1), 5 µg-1Inj-Alum, 5 µg-2Inj-Alum, 20 µg-1Inj-Alum, 20 µg-2Inj-Alum (Cohort 2).
Group 2: 5 µg-1Inj-MF59_F, 5 µg-2Inj-MF59_F, 20 µg-1Inj-MF59_F, 20 µg-2Inj-MF59_F (Cohort 3), 5 µg-1Inj-MF59_H, 5 µg-2Inj-MF59_H, 20 µg-1Inj-MF59_H, 20 µg-2Inj-MF59_H (Cohort 4)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5 µg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P2">
          <title>5 µg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="P3">
          <title>20 µg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P4">
          <title>20 µg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="P5">
          <title>5 µg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P6">
          <title>5 µg-2 Inj - Alum</title>
          <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="P7">
          <title>20 µg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P8">
          <title>20 µg-2 Inj- Alum</title>
          <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="P9">
          <title>Placebo - Group 1</title>
          <description>Subjects received two injections of placebo administered 1 month apart</description>
        </group>
        <group group_id="P10">
          <title>5 µg-1 Inj – MF59_H</title>
          <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P11">
          <title>5 µg-2 Inj – MF59_H</title>
          <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="P12">
          <title>20 µg-1 Inj – MF59_H</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P13">
          <title>20 µg-2 Inj – MF59_H</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="P14">
          <title>5 µg-1 Inj – MF59_F</title>
          <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P15">
          <title>5 µg-2 Inj – MF59_F</title>
          <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="P16">
          <title>20 µg-1 Inj – MF59_F</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="P17">
          <title>20 µg-2 Inj- MF59_F</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="P18">
          <title>Placebo – Group 2</title>
          <description>Subjects received two injections of placebo administered 1 month apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="40"/>
                <participants group_id="P11" count="40"/>
                <participants group_id="P12" count="40"/>
                <participants group_id="P13" count="40"/>
                <participants group_id="P14" count="40"/>
                <participants group_id="P15" count="40"/>
                <participants group_id="P16" count="40"/>
                <participants group_id="P17" count="40"/>
                <participants group_id="P18" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="37"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="39"/>
                <participants group_id="P11" count="38"/>
                <participants group_id="P12" count="39"/>
                <participants group_id="P13" count="37"/>
                <participants group_id="P14" count="40"/>
                <participants group_id="P15" count="40"/>
                <participants group_id="P16" count="39"/>
                <participants group_id="P17" count="40"/>
                <participants group_id="P18" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5μg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B2">
          <title>5μg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="B3">
          <title>20 μg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B4">
          <title>20 μg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="B5">
          <title>5μg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B6">
          <title>5μg-2 Inj - Alum</title>
          <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="B7">
          <title>20 μg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B8">
          <title>20 μg-2 Inj- Alum</title>
          <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="B9">
          <title>Placebo - Group 1</title>
          <description>Subjects received two injections of placebo administered 1 month apart t</description>
        </group>
        <group group_id="B10">
          <title>5μg-1 Inj –MF59_H</title>
          <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B11">
          <title>5μg-2 Inj –MF59_H</title>
          <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="B12">
          <title>20 μg-1 Inj –MF59_H</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B13">
          <title>20 μg-2 Inj –MF59_H</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="B14">
          <title>5μg-1 Inj –MF59_F</title>
          <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B15">
          <title>5μg-2 Inj –MF59_F</title>
          <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="B16">
          <title>20 μg-1 Inj –MF59_F</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="B17">
          <title>20 μg-2 Inj-MF59_F</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="B18">
          <title>Placebo – Group 2</title>
          <description>Subjects received two injections of placebo administered 1 month apart</description>
        </group>
        <group group_id="B19">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="39"/>
            <count group_id="B8" value="40"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="40"/>
            <count group_id="B11" value="40"/>
            <count group_id="B12" value="40"/>
            <count group_id="B13" value="40"/>
            <count group_id="B14" value="40"/>
            <count group_id="B15" value="40"/>
            <count group_id="B16" value="40"/>
            <count group_id="B17" value="40"/>
            <count group_id="B18" value="20"/>
            <count group_id="B19" value="678"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="5.5"/>
                    <measurement group_id="B2" value="26.2" spread="7.2"/>
                    <measurement group_id="B3" value="25.5" spread="5.0"/>
                    <measurement group_id="B4" value="24.1" spread="4.6"/>
                    <measurement group_id="B5" value="26.5" spread="6.2"/>
                    <measurement group_id="B6" value="25.1" spread="5.3"/>
                    <measurement group_id="B7" value="25.1" spread="6.3"/>
                    <measurement group_id="B8" value="24.3" spread="6.0"/>
                    <measurement group_id="B9" value="23.5" spread="3.2"/>
                    <measurement group_id="B10" value="23.4" spread="4.1"/>
                    <measurement group_id="B11" value="23.5" spread="5.7"/>
                    <measurement group_id="B12" value="23.5" spread="5.2"/>
                    <measurement group_id="B13" value="24.7" spread="6.1"/>
                    <measurement group_id="B14" value="23.6" spread="5.0"/>
                    <measurement group_id="B15" value="24.9" spread="5.9"/>
                    <measurement group_id="B16" value="22.7" spread="4.0"/>
                    <measurement group_id="B17" value="22.9" spread="5.8"/>
                    <measurement group_id="B18" value="23.5" spread="5.3"/>
                    <measurement group_id="B19" value="24.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="40"/>
                    <measurement group_id="B11" value="40"/>
                    <measurement group_id="B12" value="40"/>
                    <measurement group_id="B13" value="40"/>
                    <measurement group_id="B14" value="40"/>
                    <measurement group_id="B15" value="40"/>
                    <measurement group_id="B16" value="40"/>
                    <measurement group_id="B17" value="40"/>
                    <measurement group_id="B18" value="20"/>
                    <measurement group_id="B19" value="678"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Group 1</title>
        <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL as determined by ELISA at day 61 across cohorts 1 and 2 for potential use in pregnant women.</description>
        <time_frame>Day 1 and Day 61</time_frame>
        <population>Analysis was done on primary Per Protocol Set (PPS) - The subjects who received the vaccine correctly; provided evaluable serum samples at baseline and Day 61; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Group 1</title>
          <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL as determined by ELISA at day 61 across cohorts 1 and 2 for potential use in pregnant women.</description>
          <population>Analysis was done on primary Per Protocol Set (PPS) - The subjects who received the vaccine correctly; provided evaluable serum samples at baseline and Day 61; and had no major protocol violations as defined prior to analysis.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Serogroup Ia;N=40,33,33,35,33,32,34,35,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (Serogroup Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="95"/>
                    <measurement group_id="O7" value="87"/>
                    <measurement group_id="O8" value="84"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serogroup Ib; N=37,33,34,35,34,32,34,32,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (Serogroup Ib;N=39,38,35,38,37,37,38,36,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="86"/>
                    <measurement group_id="O7" value="84"/>
                    <measurement group_id="O8" value="64"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serogroup III;N=40,38,35,38,37,36,38,38,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (SerogroupIII;N=40,37,35,38,36,37,37,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="86"/>
                    <measurement group_id="O7" value="70"/>
                    <measurement group_id="O8" value="76"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 61</title>
        <description>Serotype–specific (Ia, Ib &amp; III) group B streptococcus (GBS) IgG antibody levels in healthy subjects for potential use in pregnant woman was assessed in terms of Geometric Mean Concentrations (GMCs) at Day 61 in cohorts 1 and 2.</description>
        <time_frame>Day 1 and Day 61</time_frame>
        <population>Analysis was done on Primary PPS</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 61</title>
          <description>Serotype–specific (Ia, Ib &amp; III) group B streptococcus (GBS) IgG antibody levels in healthy subjects for potential use in pregnant woman was assessed in terms of Geometric Mean Concentrations (GMCs) at Day 61 in cohorts 1 and 2.</description>
          <population>Analysis was done on Primary PPS</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Serotype Ia; N=40,33,33,35,33,32,34,35,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.36" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.28" upper_limit="0.94"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.21" upper_limit="0.71"/>
                    <measurement group_id="O4" value="0.45" lower_limit="0.25" upper_limit="0.81"/>
                    <measurement group_id="O5" value="0.48" lower_limit="0.26" upper_limit="0.87"/>
                    <measurement group_id="O6" value="0.57" lower_limit="0.31" upper_limit="1.06"/>
                    <measurement group_id="O7" value="0.54" lower_limit="0.29" upper_limit="0.98"/>
                    <measurement group_id="O8" value="0.37" lower_limit="0.2" upper_limit="0.67"/>
                    <measurement group_id="O9" value="0.25" lower_limit="0.11" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (Serotype Ia; N=40,38,35,38,37,37,38,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="9.42" upper_limit="41"/>
                    <measurement group_id="O2" value="11" lower_limit="5.41" upper_limit="24"/>
                    <measurement group_id="O3" value="15" lower_limit="7.08" upper_limit="34"/>
                    <measurement group_id="O4" value="18" lower_limit="8.34" upper_limit="37"/>
                    <measurement group_id="O5" value="14" lower_limit="6.54" upper_limit="30"/>
                    <measurement group_id="O6" value="9.99" lower_limit="4.67" upper_limit="21"/>
                    <measurement group_id="O7" value="9.64" lower_limit="4.55" upper_limit="20"/>
                    <measurement group_id="O8" value="6.49" lower_limit="3.03" upper_limit="14"/>
                    <measurement group_id="O9" value="0.25" lower_limit="0.083" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serotype Ib; N=37,33,34,35,34,32,34,32,17 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.089" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.065" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.11" lower_limit="0.064" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.062" upper_limit="0.18"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.088" upper_limit="0.26"/>
                    <measurement group_id="O6" value="0.12" lower_limit="0.068" upper_limit="0.21"/>
                    <measurement group_id="O7" value="0.12" lower_limit="0.072" upper_limit="0.21"/>
                    <measurement group_id="O8" value="0.081" lower_limit="0.046" upper_limit="0.14"/>
                    <measurement group_id="O9" value="0.16" lower_limit="0.072" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61(Serotype Ib;N=39,38,35,38,37,37,38,36,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.75" lower_limit="3.21" upper_limit="14"/>
                    <measurement group_id="O2" value="4.56" lower_limit="2.15" upper_limit="9.69"/>
                    <measurement group_id="O3" value="4.26" lower_limit="1.95" upper_limit="9.34"/>
                    <measurement group_id="O4" value="4.45" lower_limit="2.09" upper_limit="9.44"/>
                    <measurement group_id="O5" value="4.72" lower_limit="2.2" upper_limit="10"/>
                    <measurement group_id="O6" value="3.85" lower_limit="1.79" upper_limit="8.24"/>
                    <measurement group_id="O7" value="3.92" lower_limit="1.85" upper_limit="8.32"/>
                    <measurement group_id="O8" value="2.06" lower_limit="0.95" upper_limit="4.46"/>
                    <measurement group_id="O9" value="0.24" lower_limit="0.075" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serotype III; N=40,38,35,38,37,36,38,38,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.08" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.089" lower_limit="0.056" upper_limit="0.14"/>
                    <measurement group_id="O3" value="0.087" lower_limit="0.054" upper_limit="0.14"/>
                    <measurement group_id="O4" value="0.077" lower_limit="0.049" upper_limit="0.12"/>
                    <measurement group_id="O5" value="0.099" lower_limit="0.062" upper_limit="0.16"/>
                    <measurement group_id="O6" value="0.15" lower_limit="0.096" upper_limit="0.25"/>
                    <measurement group_id="O7" value="0.09" lower_limit="0.057" upper_limit="0.14"/>
                    <measurement group_id="O8" value="0.12" lower_limit="0.074" upper_limit="0.19"/>
                    <measurement group_id="O9" value="0.1" lower_limit="0.05" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61(Serotype III; N=40,37,35,38,36,37,37,37,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="1.6" upper_limit="6.68"/>
                    <measurement group_id="O2" value="3.23" lower_limit="1.54" upper_limit="6.78"/>
                    <measurement group_id="O3" value="2.31" lower_limit="1.08" upper_limit="4.95"/>
                    <measurement group_id="O4" value="2.35" lower_limit="1.13" upper_limit="4.89"/>
                    <measurement group_id="O5" value="1.49" lower_limit="0.7" upper_limit="3.15"/>
                    <measurement group_id="O6" value="4.3" lower_limit="2.05" upper_limit="9.04"/>
                    <measurement group_id="O7" value="1.4" lower_limit="0.67" upper_limit="2.94"/>
                    <measurement group_id="O8" value="3.28" lower_limit="1.56" upper_limit="6.89"/>
                    <measurement group_id="O9" value="0.1" lower_limit="0.035" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Adverse Events (AEs) After Receiving the GBS Trivalent Vaccine in Enrollment Group 1</title>
        <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving trivalent GBS vaccine from day 1 to day 7 for subjects across cohorts 1 and 2.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Analysis was done on Solicited Safety Set - All subjects in the Exposed Set who provided data on post vaccination local or systemic AEs or other signs of reactogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Adverse Events (AEs) After Receiving the GBS Trivalent Vaccine in Enrollment Group 1</title>
          <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving trivalent GBS vaccine from day 1 to day 7 for subjects across cohorts 1 and 2.</description>
          <population>Analysis was done on Solicited Safety Set - All subjects in the Exposed Set who provided data on post vaccination local or systemic AEs or other signs of reactogenicity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype</title>
        <description>Geometric mean ratios (GMRs) relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels measured at Day 61 for subjects across cohorts 1 and 2.</description>
        <time_frame>Day 61/Day 1</time_frame>
        <population>Analysis was done on Primary PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5 µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype</title>
          <description>Geometric mean ratios (GMRs) relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels measured at Day 61 for subjects across cohorts 1 and 2.</description>
          <population>Analysis was done on Primary PPS.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>serotype Ia; N=40,33,32,35,33,32,34,35,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="19" upper_limit="53"/>
                    <measurement group_id="O2" value="28" lower_limit="16" upper_limit="50"/>
                    <measurement group_id="O3" value="37" lower_limit="21" upper_limit="66"/>
                    <measurement group_id="O4" value="45" lower_limit="26" upper_limit="78"/>
                    <measurement group_id="O5" value="36" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="O6" value="23" lower_limit="13" upper_limit="42"/>
                    <measurement group_id="O7" value="25" lower_limit="14" upper_limit="44"/>
                    <measurement group_id="O8" value="19" lower_limit="11" upper_limit="33"/>
                    <measurement group_id="O9" value="1.01" lower_limit="0.46" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ib; N=37,33,33,35,34,32,34,31,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="29" upper_limit="77"/>
                    <measurement group_id="O2" value="46" lower_limit="27" upper_limit="78"/>
                    <measurement group_id="O3" value="39" lower_limit="23" upper_limit="66"/>
                    <measurement group_id="O4" value="47" lower_limit="28" upper_limit="79"/>
                    <measurement group_id="O5" value="38" lower_limit="22" upper_limit="63"/>
                    <measurement group_id="O6" value="32" lower_limit="19" upper_limit="54"/>
                    <measurement group_id="O7" value="33" lower_limit="20" upper_limit="55"/>
                    <measurement group_id="O8" value="23" lower_limit="13" upper_limit="39"/>
                    <measurement group_id="O9" value="1.55" lower_limit="0.73" upper_limit="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="16" upper_limit="43"/>
                    <measurement group_id="O2" value="36" lower_limit="22" upper_limit="61"/>
                    <measurement group_id="O3" value="26" lower_limit="15" upper_limit="45"/>
                    <measurement group_id="O4" value="30" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="O5" value="15" lower_limit="8.71" upper_limit="25"/>
                    <measurement group_id="O6" value="30" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="O7" value="16" lower_limit="9.48" upper_limit="26"/>
                    <measurement group_id="O8" value="30" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="O9" value="1.13" lower_limit="0.52" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Groups 1 &amp; 2</title>
        <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL at day 361 across all the cohorts for potential use in non-pregnant women.</description>
        <time_frame>Day 1 and Day 361</time_frame>
        <population>Analysis was done on Co-primary PPS - The subjects who received the vaccine correctly; provided evaluable serum samples at baseline and Day 361; and had no major protocol violations as defined prior to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
          <group group_id="O10">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O11">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O12">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O13">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O14">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O15">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O16">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O17">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O18">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Groups 1 &amp; 2</title>
          <description>The percentage of subjects achieving a specific threshold of antibody concentrations of ≥ 0.5 µg/mL at day 361 across all the cohorts for potential use in non-pregnant women.</description>
          <population>Analysis was done on Co-primary PPS - The subjects who received the vaccine correctly; provided evaluable serum samples at baseline and Day 361; and had no major protocol violations as defined prior to analysis</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="17"/>
                <count group_id="O10" value="37"/>
                <count group_id="O11" value="38"/>
                <count group_id="O12" value="38"/>
                <count group_id="O13" value="39"/>
                <count group_id="O14" value="38"/>
                <count group_id="O15" value="37"/>
                <count group_id="O16" value="38"/>
                <count group_id="O17" value="39"/>
                <count group_id="O18" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Serogroup Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="30"/>
                    <measurement group_id="O11" value="29"/>
                    <measurement group_id="O12" value="16"/>
                    <measurement group_id="O13" value="28"/>
                    <measurement group_id="O14" value="29"/>
                    <measurement group_id="O15" value="38"/>
                    <measurement group_id="O16" value="21"/>
                    <measurement group_id="O17" value="31"/>
                    <measurement group_id="O18" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (Serogroup Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="92"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="75"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="78"/>
                    <measurement group_id="O11" value="82"/>
                    <measurement group_id="O12" value="76"/>
                    <measurement group_id="O13" value="95"/>
                    <measurement group_id="O14" value="69"/>
                    <measurement group_id="O15" value="92"/>
                    <measurement group_id="O16" value="76"/>
                    <measurement group_id="O17" value="90"/>
                    <measurement group_id="O18" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serogroup Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="24"/>
                    <measurement group_id="O11" value="15"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="26"/>
                    <measurement group_id="O14" value="23"/>
                    <measurement group_id="O15" value="19"/>
                    <measurement group_id="O16" value="6"/>
                    <measurement group_id="O17" value="11"/>
                    <measurement group_id="O18" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (Serogroup Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="89"/>
                    <measurement group_id="O9" value="46"/>
                    <measurement group_id="O10" value="92"/>
                    <measurement group_id="O11" value="100"/>
                    <measurement group_id="O12" value="87"/>
                    <measurement group_id="O13" value="97"/>
                    <measurement group_id="O14" value="95"/>
                    <measurement group_id="O15" value="97"/>
                    <measurement group_id="O16" value="100"/>
                    <measurement group_id="O17" value="100"/>
                    <measurement group_id="O18" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Serogroup III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="11"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="8"/>
                    <measurement group_id="O14" value="14"/>
                    <measurement group_id="O15" value="14"/>
                    <measurement group_id="O16" value="11"/>
                    <measurement group_id="O17" value="8"/>
                    <measurement group_id="O18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (Serogroup III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="95"/>
                    <measurement group_id="O7" value="87"/>
                    <measurement group_id="O8" value="89"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="86"/>
                    <measurement group_id="O11" value="95"/>
                    <measurement group_id="O12" value="92"/>
                    <measurement group_id="O13" value="100"/>
                    <measurement group_id="O14" value="87"/>
                    <measurement group_id="O15" value="100"/>
                    <measurement group_id="O16" value="89"/>
                    <measurement group_id="O17" value="92"/>
                    <measurement group_id="O18" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 361</title>
        <description>Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant woman was assessed in terms of GMCs at Day 361 across all cohorts.</description>
        <time_frame>Day 1 and Day 361</time_frame>
        <population>Analysis was done on Co-Primary PPS</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5 µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
          <group group_id="O10">
            <title>5 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O11">
            <title>5 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O12">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O13">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O14">
            <title>5 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O15">
            <title>5 µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O16">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O17">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O18">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Serum Anti-GBS IgG Antibody Levels by Serotype at Day 361</title>
          <description>Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant woman was assessed in terms of GMCs at Day 361 across all cohorts.</description>
          <population>Analysis was done on Co-Primary PPS</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="17"/>
                <count group_id="O10" value="37"/>
                <count group_id="O11" value="38"/>
                <count group_id="O12" value="38"/>
                <count group_id="O13" value="39"/>
                <count group_id="O14" value="39"/>
                <count group_id="O15" value="37"/>
                <count group_id="O16" value="38"/>
                <count group_id="O17" value="39"/>
                <count group_id="O18" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.36" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.25" upper_limit="0.84"/>
                    <measurement group_id="O3" value="0.36" lower_limit="0.2" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.45" lower_limit="0.25" upper_limit="0.8"/>
                    <measurement group_id="O5" value="0.53" lower_limit="0.29" upper_limit="0.96"/>
                    <measurement group_id="O6" value="0.62" lower_limit="0.34" upper_limit="1.14"/>
                    <measurement group_id="O7" value="0.54" lower_limit="0.3" upper_limit="0.97"/>
                    <measurement group_id="O8" value="0.37" lower_limit="0.21" upper_limit="0.66"/>
                    <measurement group_id="O9" value="0.25" lower_limit="0.11" upper_limit="0.58"/>
                    <measurement group_id="O10" value="0.54" lower_limit="0.32" upper_limit="0.91"/>
                    <measurement group_id="O11" value="0.43" lower_limit="0.25" upper_limit="0.72"/>
                    <measurement group_id="O12" value="0.27" lower_limit="0.16" upper_limit="0.45"/>
                    <measurement group_id="O13" value="0.36" lower_limit="0.22" upper_limit="0.61"/>
                    <measurement group_id="O14" value="0.44" lower_limit="0.26" upper_limit="0.73"/>
                    <measurement group_id="O15" value="0.46" lower_limit="0.27" upper_limit="0.79"/>
                    <measurement group_id="O16" value="0.36" lower_limit="0.21" upper_limit="0.6"/>
                    <measurement group_id="O17" value="0.45" lower_limit="0.27" upper_limit="0.75"/>
                    <measurement group_id="O18" value="0.34" lower_limit="0.17" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day361(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" lower_limit="2.93" upper_limit="12"/>
                    <measurement group_id="O2" value="3.78" lower_limit="1.85" upper_limit="7.72"/>
                    <measurement group_id="O3" value="4" lower_limit="1.9" upper_limit="8.41"/>
                    <measurement group_id="O4" value="4.6" lower_limit="2.25" upper_limit="9.38"/>
                    <measurement group_id="O5" value="5.83" lower_limit="2.86" upper_limit="12"/>
                    <measurement group_id="O6" value="5.22" lower_limit="2.56" upper_limit="11"/>
                    <measurement group_id="O7" value="3.78" lower_limit="1.87" upper_limit="7.65"/>
                    <measurement group_id="O8" value="2.94" lower_limit="1.43" upper_limit="6.05"/>
                    <measurement group_id="O9" value="0.26" lower_limit="0.08" upper_limit="0.81"/>
                    <measurement group_id="O10" value="3.62" lower_limit="1.84" upper_limit="7.13"/>
                    <measurement group_id="O11" value="3.04" lower_limit="1.56" upper_limit="5.93"/>
                    <measurement group_id="O12" value="2.13" lower_limit="1.09" upper_limit="4.15"/>
                    <measurement group_id="O13" value="7.19" lower_limit="3.72" upper_limit="14"/>
                    <measurement group_id="O14" value="2.65" lower_limit="1.37" upper_limit="5.12"/>
                    <measurement group_id="O15" value="7.32" lower_limit="3.72" upper_limit="14"/>
                    <measurement group_id="O16" value="2.67" lower_limit="1.36" upper_limit="5.24"/>
                    <measurement group_id="O17" value="4.41" lower_limit="2.28" upper_limit="8.52"/>
                    <measurement group_id="O18" value="0.31" lower_limit="0.12" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.089" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.066" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.099" lower_limit="0.058" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.062" upper_limit="0.18"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.085" upper_limit="0.25"/>
                    <measurement group_id="O6" value="0.12" lower_limit="0.069" upper_limit="0.2"/>
                    <measurement group_id="O7" value="0.12" lower_limit="0.073" upper_limit="0.21"/>
                    <measurement group_id="O8" value="0.079" lower_limit="0.046" upper_limit="0.14"/>
                    <measurement group_id="O9" value="0.16" lower_limit="0.073" upper_limit="0.33"/>
                    <measurement group_id="O10" value="0.12" lower_limit="0.071" upper_limit="0.21"/>
                    <measurement group_id="O11" value="0.1" lower_limit="0.058" upper_limit="0.17"/>
                    <measurement group_id="O12" value="0.07" lower_limit="0.04" upper_limit="0.12"/>
                    <measurement group_id="O13" value="0.11" lower_limit="0.062" upper_limit="0.18"/>
                    <measurement group_id="O14" value="0.15" lower_limit="0.083" upper_limit="0.26"/>
                    <measurement group_id="O15" value="0.11" lower_limit="0.065" upper_limit="0.2"/>
                    <measurement group_id="O16" value="0.077" lower_limit="0.044" upper_limit="0.13"/>
                    <measurement group_id="O17" value="0.09" lower_limit="0.053" upper_limit="0.15"/>
                    <measurement group_id="O18" value="0.1" lower_limit="0.048" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day361(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" lower_limit="2.38" upper_limit="6.83"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.15" upper_limit="6.36"/>
                    <measurement group_id="O3" value="2.86" lower_limit="1.62" upper_limit="5.03"/>
                    <measurement group_id="O4" value="3.82" lower_limit="2.22" upper_limit="6.58"/>
                    <measurement group_id="O5" value="3.13" lower_limit="1.82" upper_limit="5.38"/>
                    <measurement group_id="O6" value="4.59" lower_limit="2.67" upper_limit="7.89"/>
                    <measurement group_id="O7" value="3.38" lower_limit="1.98" upper_limit="5.77"/>
                    <measurement group_id="O8" value="2.45" lower_limit="1.41" upper_limit="4.24"/>
                    <measurement group_id="O9" value="0.81" lower_limit="0.33" upper_limit="2.03"/>
                    <measurement group_id="O10" value="2.67" lower_limit="1.53" upper_limit="4.66"/>
                    <measurement group_id="O11" value="3.81" lower_limit="2.19" upper_limit="6.61"/>
                    <measurement group_id="O12" value="1.88" lower_limit="1.08" upper_limit="3.27"/>
                    <measurement group_id="O13" value="5.53" lower_limit="3.21" upper_limit="9.54"/>
                    <measurement group_id="O14" value="3.18" lower_limit="1.85" upper_limit="5.48"/>
                    <measurement group_id="O15" value="5.19" lower_limit="2.97" upper_limit="9.08"/>
                    <measurement group_id="O16" value="3.9" lower_limit="2.23" upper_limit="6.82"/>
                    <measurement group_id="O17" value="3.64" lower_limit="2.11" upper_limit="6.27"/>
                    <measurement group_id="O18" value="0.18" lower_limit="0.079" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1(serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.08" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.091" lower_limit="0.057" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.089" lower_limit="0.055" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.077" lower_limit="0.049" upper_limit="0.12"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0.064" upper_limit="0.16"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.1" upper_limit="0.26"/>
                    <measurement group_id="O7" value="0.09" lower_limit="0.057" upper_limit="0.14"/>
                    <measurement group_id="O8" value="0.12" lower_limit="0.074" upper_limit="0.19"/>
                    <measurement group_id="O9" value="0.1" lower_limit="0.05" upper_limit="0.2"/>
                    <measurement group_id="O10" value="0.1" lower_limit="0.066" upper_limit="0.17"/>
                    <measurement group_id="O11" value="0.079" lower_limit="0.05" upper_limit="0.13"/>
                    <measurement group_id="O12" value="0.058" lower_limit="0.037" upper_limit="0.092"/>
                    <measurement group_id="O13" value="0.067" lower_limit="0.042" upper_limit="0.11"/>
                    <measurement group_id="O14" value="0.1" lower_limit="0.066" upper_limit="0.16"/>
                    <measurement group_id="O15" value="0.11" lower_limit="0.067" upper_limit="0.17"/>
                    <measurement group_id="O16" value="0.078" lower_limit="0.049" upper_limit="0.12"/>
                    <measurement group_id="O17" value="0.093" lower_limit="0.059" upper_limit="0.15"/>
                    <measurement group_id="O18" value="0.068" lower_limit="0.036" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day361(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="1.78" upper_limit="5.2"/>
                    <measurement group_id="O2" value="2.71" lower_limit="1.57" upper_limit="4.69"/>
                    <measurement group_id="O3" value="2.45" lower_limit="1.38" upper_limit="4.34"/>
                    <measurement group_id="O4" value="2.78" lower_limit="1.61" upper_limit="4.81"/>
                    <measurement group_id="O5" value="1.77" lower_limit="1.02" upper_limit="3.07"/>
                    <measurement group_id="O6" value="4.48" lower_limit="2.59" upper_limit="7.76"/>
                    <measurement group_id="O7" value="1.77" lower_limit="1.03" upper_limit="3.03"/>
                    <measurement group_id="O8" value="3.46" lower_limit="1.98" upper_limit="6.04"/>
                    <measurement group_id="O9" value="0.13" lower_limit="0.054" upper_limit="0.3"/>
                    <measurement group_id="O10" value="2.33" lower_limit="1.42" upper_limit="3.8"/>
                    <measurement group_id="O11" value="2.67" lower_limit="1.64" upper_limit="4.34"/>
                    <measurement group_id="O12" value="2.06" lower_limit="1.27" upper_limit="3.34"/>
                    <measurement group_id="O13" value="4.5" lower_limit="2.78" upper_limit="7.26"/>
                    <measurement group_id="O14" value="2.62" lower_limit="1.62" upper_limit="4.23"/>
                    <measurement group_id="O15" value="4.99" lower_limit="3.05" upper_limit="8.17"/>
                    <measurement group_id="O16" value="3.07" lower_limit="1.87" upper_limit="5.02"/>
                    <measurement group_id="O17" value="3.51" lower_limit="2.17" upper_limit="5.67"/>
                    <measurement group_id="O18" value="0.076" lower_limit="0.038" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype at Day 361</title>
        <description>GMRs relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant women, measured at Day 361 across all cohorts.</description>
        <time_frame>Day 1 and day 361</time_frame>
        <population>Analysis was done on Co-Primary PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
          <group group_id="O10">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O11">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O12">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O13">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O14">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O15">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O16">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O17">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O18">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios of Serum Group B Streptococcus IgG Antibody Levels By Serotype at Day 361</title>
          <description>GMRs relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels in healthy subjects for potential use in non-pregnant women, measured at Day 361 across all cohorts.</description>
          <population>Analysis was done on Co-Primary PPS.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="37"/>
                <count group_id="O11" value="38"/>
                <count group_id="O12" value="38"/>
                <count group_id="O13" value="39"/>
                <count group_id="O14" value="38"/>
                <count group_id="O15" value="37"/>
                <count group_id="O16" value="37"/>
                <count group_id="O17" value="39"/>
                <count group_id="O18" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day361/Day1(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" lower_limit="5.74" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="6.09" upper_limit="17"/>
                    <measurement group_id="O3" value="9.89" lower_limit="5.87" upper_limit="17"/>
                    <measurement group_id="O4" value="15" lower_limit="8.9" upper_limit="24"/>
                    <measurement group_id="O5" value="14" lower_limit="8.3" upper_limit="23"/>
                    <measurement group_id="O6" value="11" lower_limit="6.58" upper_limit="18"/>
                    <measurement group_id="O7" value="8.93" lower_limit="5.43" upper_limit="15"/>
                    <measurement group_id="O8" value="9.54" lower_limit="5.8" upper_limit="16"/>
                    <measurement group_id="O9" value="0.93" lower_limit="0.43" upper_limit="2.01"/>
                    <measurement group_id="O10" value="6.75" lower_limit="4.44" upper_limit="10"/>
                    <measurement group_id="O11" value="7.15" lower_limit="4.73" upper_limit="11"/>
                    <measurement group_id="O12" value="7.99" lower_limit="5.29" upper_limit="12"/>
                    <measurement group_id="O13" value="20" lower_limit="13" upper_limit="30"/>
                    <measurement group_id="O14" value="6.17" lower_limit="4.09" upper_limit="9.33"/>
                    <measurement group_id="O15" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O16" value="7.29" lower_limit="4.8" upper_limit="11"/>
                    <measurement group_id="O17" value="9.83" lower_limit="6.54" upper_limit="15"/>
                    <measurement group_id="O18" value="0.9" lower_limit="0.51" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day361/Day1(Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="19" upper_limit="40"/>
                    <measurement group_id="O2" value="37" lower_limit="26" upper_limit="55"/>
                    <measurement group_id="O3" value="26" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="O4" value="38" lower_limit="26" upper_limit="55"/>
                    <measurement group_id="O5" value="23" lower_limit="16" upper_limit="34"/>
                    <measurement group_id="O6" value="38" lower_limit="26" upper_limit="55"/>
                    <measurement group_id="O7" value="27" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="O8" value="30" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="O9" value="3.97" lower_limit="2.19" upper_limit="7.19"/>
                    <measurement group_id="O10" value="23" lower_limit="16" upper_limit="33"/>
                    <measurement group_id="O11" value="37" lower_limit="26" upper_limit="53"/>
                    <measurement group_id="O12" value="27" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="O13" value="54" lower_limit="38" upper_limit="76"/>
                    <measurement group_id="O14" value="26" lower_limit="18" upper_limit="37"/>
                    <measurement group_id="O15" value="45" lower_limit="31" upper_limit="66"/>
                    <measurement group_id="O16" value="49" lower_limit="34" upper_limit="71"/>
                    <measurement group_id="O17" value="35" lower_limit="25" upper_limit="50"/>
                    <measurement group_id="O18" value="1.75" lower_limit="1.04" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day361/Day1(Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="16" upper_limit="35"/>
                    <measurement group_id="O2" value="30" lower_limit="20" upper_limit="45"/>
                    <measurement group_id="O3" value="27" lower_limit="17" upper_limit="41"/>
                    <measurement group_id="O4" value="35" lower_limit="23" upper_limit="53"/>
                    <measurement group_id="O5" value="17" lower_limit="12" upper_limit="26"/>
                    <measurement group_id="O6" value="30" lower_limit="20" upper_limit="45"/>
                    <measurement group_id="O7" value="20" lower_limit="13" upper_limit="29"/>
                    <measurement group_id="O8" value="31" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O9" value="1.4" lower_limit="0.72" upper_limit="2.72"/>
                    <measurement group_id="O10" value="22" lower_limit="15" upper_limit="33"/>
                    <measurement group_id="O11" value="35" lower_limit="23" upper_limit="53"/>
                    <measurement group_id="O12" value="35" lower_limit="24" upper_limit="53"/>
                    <measurement group_id="O13" value="65" lower_limit="44" upper_limit="97"/>
                    <measurement group_id="O14" value="26" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="O15" value="45" lower_limit="30" upper_limit="68"/>
                    <measurement group_id="O16" value="38" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="O17" value="38" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="O18" value="1.24" lower_limit="0.7" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited AEs After Receiving the GBS Trivalent Vaccine in Enrollment Group 2</title>
        <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving GBS vaccine from day 1 to day 7 for subjects in cohorts 3 and 4.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Analysis was done on Solicited Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited AEs After Receiving the GBS Trivalent Vaccine in Enrollment Group 2</title>
          <description>Safety was assessed in terms of number of participants reporting solicited local and systemic adverse events after receiving GBS vaccine from day 1 to day 7 for subjects in cohorts 3 and 4.</description>
          <population>Analysis was done on Solicited Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 1</title>
        <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 1 and 2.</description>
        <time_frame>Day 1 through Day 721</time_frame>
        <population>Analysis was done on unsolicited safety set - All subjects in the Exposed Set who provided information about postvaccination unsolicited AEs.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 1</title>
          <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 1 and 2.</description>
          <population>Analysis was done on unsolicited safety set - All subjects in the Exposed Set who provided information about postvaccination unsolicited AEs.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="39"/>
                <count group_id="O9" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="33"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 2</title>
        <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 3 and 4.</description>
        <time_frame>Day 1 through Day 721</time_frame>
        <population>Analysis was done on Unsolicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Unsolicited AE After Receiving GBS Trivalent Vaccine in Enrollment Group 2</title>
          <description>Safety was assessed in terms of number of participants with unsolicited AEs after receiving GBS trivalent vaccine, reported from day 1 to day 721 across subjects in cohorts 3 and 4.</description>
          <population>Analysis was done on Unsolicited Safety Set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype for Subjects in Enrollment Group 1</title>
        <description>The persistence of Serotype–specific (Ia, Ib &amp; III) GBS IgG antibody response was assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohorts 1 and 2.</description>
        <time_frame>Day 1 and Day 721</time_frame>
        <population>Analysis was done on secondary persistence PPS - All the subjects who provided all serum sample results from Baseline (prior to vaccination) through Day 721 within protocol required windows.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype for Subjects in Enrollment Group 1</title>
          <description>The persistence of Serotype–specific (Ia, Ib &amp; III) GBS IgG antibody response was assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohorts 1 and 2.</description>
          <population>Analysis was done on secondary persistence PPS - All the subjects who provided all serum sample results from Baseline (prior to vaccination) through Day 721 within protocol required windows.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.35" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.25" upper_limit="0.83"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.21" upper_limit="0.75"/>
                    <measurement group_id="O4" value="0.34" lower_limit="0.19" upper_limit="0.64"/>
                    <measurement group_id="O5" value="0.55" lower_limit="0.29" upper_limit="1.04"/>
                    <measurement group_id="O6" value="0.49" lower_limit="0.25" upper_limit="0.95"/>
                    <measurement group_id="O7" value="0.56" lower_limit="0.31" upper_limit="1.01"/>
                    <measurement group_id="O8" value="0.34" lower_limit="0.18" upper_limit="0.63"/>
                    <measurement group_id="O9" value="0.37" lower_limit="0.12" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721 (Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="2.23" upper_limit="9.89"/>
                    <measurement group_id="O2" value="3.48" lower_limit="1.58" upper_limit="7.67"/>
                    <measurement group_id="O3" value="3.11" lower_limit="1.36" upper_limit="7.14"/>
                    <measurement group_id="O4" value="3.18" lower_limit="1.42" upper_limit="7.09"/>
                    <measurement group_id="O5" value="5.1" lower_limit="2.23" upper_limit="12"/>
                    <measurement group_id="O6" value="3.01" lower_limit="1.27" upper_limit="7.11"/>
                    <measurement group_id="O7" value="3.69" lower_limit="1.69" upper_limit="8.03"/>
                    <measurement group_id="O8" value="2.17" lower_limit="0.97" upper_limit="4.85"/>
                    <measurement group_id="O9" value="0.3" lower_limit="0.068" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1(Serotype Ib;N=32,30,28,32,29,28,28,27,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.089" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.061" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.094" lower_limit="0.051" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.063" upper_limit="0.2"/>
                    <measurement group_id="O5" value="0.18" lower_limit="0.1" upper_limit="0.33"/>
                    <measurement group_id="O6" value="0.13" lower_limit="0.069" upper_limit="0.23"/>
                    <measurement group_id="O7" value="0.14" lower_limit="0.078" upper_limit="0.27"/>
                    <measurement group_id="O8" value="0.085" lower_limit="0.045" upper_limit="0.16"/>
                    <measurement group_id="O9" value="0.88" lower_limit="0.23" upper_limit="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721(Serotype Ib;N=32,30,28,32,29,28,28,27,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="1.51" upper_limit="5.64"/>
                    <measurement group_id="O2" value="2.81" lower_limit="1.42" upper_limit="5.55"/>
                    <measurement group_id="O3" value="1.71" lower_limit="0.85" upper_limit="3.46"/>
                    <measurement group_id="O4" value="2.64" lower_limit="1.37" upper_limit="5.1"/>
                    <measurement group_id="O5" value="2.32" lower_limit="1.16" upper_limit="4.64"/>
                    <measurement group_id="O6" value="2.96" lower_limit="1.47" upper_limit="5.99"/>
                    <measurement group_id="O7" value="2.55" lower_limit="1.26" upper_limit="5.15"/>
                    <measurement group_id="O8" value="1.45" lower_limit="0.71" upper_limit="2.97"/>
                    <measurement group_id="O9" value="1.02" lower_limit="0.22" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1(Serotype III;N=34,33,28,34,30,30,34,31,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.083" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.097" lower_limit="0.058" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.094" lower_limit="0.053" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.079" lower_limit="0.047" upper_limit="0.13"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.069" upper_limit="0.21"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.095" upper_limit="0.28"/>
                    <measurement group_id="O7" value="0.095" lower_limit="0.057" upper_limit="0.16"/>
                    <measurement group_id="O8" value="0.12" lower_limit="0.07" upper_limit="0.21"/>
                    <measurement group_id="O9" value="0.071" lower_limit="0.021" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721(Serotype III;N=34,33,28,34,30,30,34,31,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="1.77" upper_limit="5.77"/>
                    <measurement group_id="O2" value="1.89" lower_limit="1.04" upper_limit="3.45"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.89" upper_limit="3.27"/>
                    <measurement group_id="O4" value="2.16" lower_limit="1.2" upper_limit="3.91"/>
                    <measurement group_id="O5" value="1.26" lower_limit="0.67" upper_limit="2.36"/>
                    <measurement group_id="O6" value="3.87" lower_limit="2.06" upper_limit="7.26"/>
                    <measurement group_id="O7" value="1.44" lower_limit="0.8" upper_limit="2.6"/>
                    <measurement group_id="O8" value="2.68" lower_limit="1.44" upper_limit="4.99"/>
                    <measurement group_id="O9" value="0.054" lower_limit="0.013" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype in Subjects in Enrollment Group 2</title>
        <description>The persistence of Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody response assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohort 3 and 4.</description>
        <time_frame>Day 1 and Day 721</time_frame>
        <population>Analysis was done on secondary persistence PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Antibody Response in Terms of Geometric Mean Concentrations by Serotype in Subjects in Enrollment Group 2</title>
          <description>The persistence of Serotype-specific (Ia, Ib &amp; III) GBS IgG antibody response assessed by comparing ELISA responses in terms of GMCs at day 721 after the first injection for subjects enrolled in cohort 3 and 4.</description>
          <population>Analysis was done on secondary persistence PPS.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.27" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.27" upper_limit="0.83"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.16" upper_limit="0.49"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.17" upper_limit="0.51"/>
                    <measurement group_id="O5" value="0.46" lower_limit="0.27" upper_limit="0.79"/>
                    <measurement group_id="O6" value="0.53" lower_limit="0.3" upper_limit="0.93"/>
                    <measurement group_id="O7" value="0.37" lower_limit="0.21" upper_limit="0.62"/>
                    <measurement group_id="O8" value="0.49" lower_limit="0.28" upper_limit="0.84"/>
                    <measurement group_id="O9" value="0.37" lower_limit="0.17" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721 (Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="0.9" upper_limit="3.83"/>
                    <measurement group_id="O2" value="1.97" lower_limit="0.95" upper_limit="4.11"/>
                    <measurement group_id="O3" value="1.73" lower_limit="0.83" upper_limit="3.6"/>
                    <measurement group_id="O4" value="3.09" lower_limit="1.49" upper_limit="6.44"/>
                    <measurement group_id="O5" value="1.66" lower_limit="0.82" upper_limit="3.39"/>
                    <measurement group_id="O6" value="5.06" lower_limit="2.4" upper_limit="11"/>
                    <measurement group_id="O7" value="1.72" lower_limit="0.85" upper_limit="3.47"/>
                    <measurement group_id="O8" value="3.32" lower_limit="1.63" upper_limit="6.77"/>
                    <measurement group_id="O9" value="0.33" lower_limit="0.12" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1(Serotype Ib;N=32,28,29,29,28,24,30,33,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.074" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.092" lower_limit="0.051" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.072" lower_limit="0.04" upper_limit="0.13"/>
                    <measurement group_id="O4" value="0.1" lower_limit="0.058" upper_limit="0.19"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.08" upper_limit="0.27"/>
                    <measurement group_id="O6" value="0.15" lower_limit="0.077" upper_limit="0.28"/>
                    <measurement group_id="O7" value="0.08" lower_limit="0.045" upper_limit="0.14"/>
                    <measurement group_id="O8" value="0.094" lower_limit="0.054" upper_limit="0.16"/>
                    <measurement group_id="O9" value="0.16" lower_limit="0.055" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721(Serotype Ib;N=32,28,29,29,28,24,30,33,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.9" upper_limit="3.22"/>
                    <measurement group_id="O2" value="1.72" lower_limit="0.87" upper_limit="3.41"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.59" upper_limit="2.27"/>
                    <measurement group_id="O4" value="2.99" lower_limit="1.53" upper_limit="5.86"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.26" upper_limit="4.96"/>
                    <measurement group_id="O6" value="4.23" lower_limit="2.02" upper_limit="8.84"/>
                    <measurement group_id="O7" value="2.47" lower_limit="1.28" upper_limit="4.79"/>
                    <measurement group_id="O8" value="1.93" lower_limit="1.03" upper_limit="3.61"/>
                    <measurement group_id="O9" value="0.21" lower_limit="0.063" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1(Serotype III;N=34,32,34,32,33,31,36,33,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.068" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.082" lower_limit="0.049" upper_limit="0.14"/>
                    <measurement group_id="O3" value="0.061" lower_limit="0.037" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.071" lower_limit="0.043" upper_limit="0.12"/>
                    <measurement group_id="O5" value="0.09" lower_limit="0.054" upper_limit="0.15"/>
                    <measurement group_id="O6" value="0.12" lower_limit="0.069" upper_limit="0.2"/>
                    <measurement group_id="O7" value="0.077" lower_limit="0.048" upper_limit="0.12"/>
                    <measurement group_id="O8" value="0.1" lower_limit="0.06" upper_limit="0.17"/>
                    <measurement group_id="O9" value="0.061" lower_limit="0.028" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day721(Serotype III;N=34,32,34,32,33,31,36,33,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1" upper_limit="2.96"/>
                    <measurement group_id="O2" value="1.59" lower_limit="0.91" upper_limit="2.79"/>
                    <measurement group_id="O3" value="1.29" lower_limit="0.75" upper_limit="2.23"/>
                    <measurement group_id="O4" value="2.48" lower_limit="1.42" upper_limit="4.33"/>
                    <measurement group_id="O5" value="2.04" lower_limit="1.17" upper_limit="3.53"/>
                    <measurement group_id="O6" value="3.18" lower_limit="1.8" upper_limit="5.61"/>
                    <measurement group_id="O7" value="1.78" lower_limit="1.05" upper_limit="3.02"/>
                    <measurement group_id="O8" value="2.05" lower_limit="1.18" upper_limit="3.56"/>
                    <measurement group_id="O9" value="0.075" lower_limit="0.032" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 1</title>
        <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across all cohorts 1 and 2.</description>
        <time_frame>Day 1 and Day 721</time_frame>
        <population>Analysis was done on secondary persistence PPS</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj - No Adj</title>
            <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj - No Adj</title>
            <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj - Alum</title>
            <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj - Alum</title>
            <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- Alum</title>
            <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo - Group 1</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 1</title>
          <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across all cohorts 1 and 2.</description>
          <population>Analysis was done on secondary persistence PPS</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 721/Day 1(Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="4.51" upper_limit="12"/>
                    <measurement group_id="O2" value="7.67" lower_limit="4.47" upper_limit="13"/>
                    <measurement group_id="O3" value="7.89" lower_limit="4.48" upper_limit="14"/>
                    <measurement group_id="O4" value="9.24" lower_limit="5.34" upper_limit="16"/>
                    <measurement group_id="O5" value="9.25" lower_limit="5.25" upper_limit="16"/>
                    <measurement group_id="O6" value="6.15" lower_limit="3.42" upper_limit="11"/>
                    <measurement group_id="O7" value="6.64" lower_limit="3.9" upper_limit="11"/>
                    <measurement group_id="O8" value="6.35" lower_limit="3.67" upper_limit="11"/>
                    <measurement group_id="O9" value="0.82" lower_limit="0.3" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721/ Day 1 (Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12" upper_limit="28"/>
                    <measurement group_id="O2" value="26" lower_limit="17" upper_limit="40"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="29"/>
                    <measurement group_id="O4" value="24" lower_limit="15" upper_limit="36"/>
                    <measurement group_id="O5" value="13" lower_limit="8.16" upper_limit="20"/>
                    <measurement group_id="O6" value="23" lower_limit="15" upper_limit="37"/>
                    <measurement group_id="O7" value="18" lower_limit="11" upper_limit="28"/>
                    <measurement group_id="O8" value="17" lower_limit="11" upper_limit="27"/>
                    <measurement group_id="O9" value="1.17" lower_limit="0.44" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721/ Day 1 (Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="30"/>
                    <measurement group_id="O3" value="18" lower_limit="11" upper_limit="29"/>
                    <measurement group_id="O4" value="27" lower_limit="18" upper_limit="41"/>
                    <measurement group_id="O5" value="11" lower_limit="6.81" upper_limit="16"/>
                    <measurement group_id="O6" value="24" lower_limit="15" upper_limit="37"/>
                    <measurement group_id="O7" value="15" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="O8" value="22" lower_limit="14" upper_limit="35"/>
                    <measurement group_id="O9" value="0.76" lower_limit="0.28" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 2</title>
        <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across cohorts 3 and 4.</description>
        <time_frame>Day 1 and Day 721</time_frame>
        <population>Analysis was done on secondary persistence PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>5µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O2">
            <title>5µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O3">
            <title>20 µg-1 Inj – MF59_H</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O4">
            <title>20 µg-2 Inj – MF59_H</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O5">
            <title>5µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O6">
            <title>5µg-2 Inj – MF59_F</title>
            <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O7">
            <title>20 µg-1 Inj – MF59_F</title>
            <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
          </group>
          <group group_id="O8">
            <title>20 µg-2 Inj- MF59_F</title>
            <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
          </group>
          <group group_id="O9">
            <title>Placebo – Group 2</title>
            <description>Subjects received two injections of placebo administered 1 month apart</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios of Serum GBS IgG Antibody Levels By Serotype for Subjects in Enrollment Group 2</title>
          <description>GMR was calculated at Day 721 relative to baseline (Day 1) of serotype-specific (Ia, Ib, III) GBS IgG antibody levels across cohorts 3 and 4.</description>
          <population>Analysis was done on secondary persistence PPS.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 721/Day 1 (Serotype Ia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="2.55" upper_limit="6.2"/>
                    <measurement group_id="O2" value="4.14" lower_limit="2.64" upper_limit="6.5"/>
                    <measurement group_id="O3" value="6.12" lower_limit="3.9" upper_limit="9.6"/>
                    <measurement group_id="O4" value="11" lower_limit="6.74" upper_limit="17"/>
                    <measurement group_id="O5" value="3.61" lower_limit="2.33" upper_limit="5.6"/>
                    <measurement group_id="O6" value="9.61" lower_limit="6.09" upper_limit="15"/>
                    <measurement group_id="O7" value="4.7" lower_limit="3.05" upper_limit="7.23"/>
                    <measurement group_id="O8" value="6.8" lower_limit="4.39" upper_limit="11"/>
                    <measurement group_id="O9" value="0.89" lower_limit="0.48" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721/Day 1 (Serotype Ib)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8.76" upper_limit="20"/>
                    <measurement group_id="O2" value="19" lower_limit="12" upper_limit="29"/>
                    <measurement group_id="O3" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O4" value="29" lower_limit="19" upper_limit="44"/>
                    <measurement group_id="O5" value="17" lower_limit="11" upper_limit="26"/>
                    <measurement group_id="O6" value="29" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="O7" value="31" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O8" value="20" lower_limit="14" upper_limit="30"/>
                    <measurement group_id="O9" value="1.31" lower_limit="0.61" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 721/Day 1 (Serotype III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O2" value="19" lower_limit="12" upper_limit="30"/>
                    <measurement group_id="O3" value="21" lower_limit="14" upper_limit="33"/>
                    <measurement group_id="O4" value="35" lower_limit="22" upper_limit="54"/>
                    <measurement group_id="O5" value="23" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O6" value="27" lower_limit="17" upper_limit="43"/>
                    <measurement group_id="O7" value="23" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O8" value="21" lower_limit="13" upper_limit="32"/>
                    <measurement group_id="O9" value="1.22" lower_limit="0.62" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Day 721</time_frame>
      <desc>All Solicited AEs are classified as systematic assessment and all unsolicited AEs are classified as non-systematic assessment.
Safety analysis was done on As treated set.</desc>
      <group_list>
        <group group_id="E1">
          <title>5µg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (5 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E2">
          <title>5µg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (5 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="E3">
          <title>20 µg-1 Inj - No Adj</title>
          <description>Subjects received single active vaccine injection (20 µg) without any adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E4">
          <title>20 µg-2 Inj - No Adj</title>
          <description>Subjects received two identical active vaccine injections (20 µg) without any adjuvant administered 1 month apart</description>
        </group>
        <group group_id="E5">
          <title>5µg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (5 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E6">
          <title>5µg-2 Inj - Alum</title>
          <description>Subjects received two identical active vaccine injections (5 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="E7">
          <title>20 µg-1 Inj - Alum</title>
          <description>Subjects received single active vaccine injection (20 µg) with adjuvant followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E8">
          <title>20 µg-2 Inj- Alum</title>
          <description>Subjects received two identical active vaccine injections (20 µg) with adjuvant administered 1 month apart</description>
        </group>
        <group group_id="E9">
          <title>Placebo - Group 1</title>
          <description>Subjects received two injections of placebo administered 1 month apart</description>
        </group>
        <group group_id="E10">
          <title>5µg-1 Inj – MF59_H</title>
          <description>Subjects received single active vaccine injection (5 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E11">
          <title>5µg-2 Inj – MF59_H</title>
          <description>Subjects received two identical active vaccine injections (5 µg) of adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="E12">
          <title>20 µg-1 Inj – MF59_H</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 4.87 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E13">
          <title>20 µg-2 Inj – MF59_H</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 4.87 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="E14">
          <title>5µg-1 Inj – MF59_F</title>
          <description>Subjects received single active vaccine injection (5 µg) of adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E15">
          <title>5µg-2 Inj – MF59_F</title>
          <description>Subjects received two identical active vaccine injections (5 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="E16">
          <title>20 µg-1 Inj – MF59_F</title>
          <description>Subjects received single active vaccine injection (20 µg) adjuvanted with 9.75 mg of MF59 followed by a placebo administered 1 month apart</description>
        </group>
        <group group_id="E17">
          <title>20 µg-2 Inj- MF59_F</title>
          <description>Subjects received two identical active vaccine injections (20 µg) adjuvanted with 9.75 mg of MF59 administered 1 month apart</description>
        </group>
        <group group_id="E18">
          <title>Placebo – Group 2</title>
          <description>Subjects received two injections of placebo administered 1 month apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tonsillitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tendon Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decompression Sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Overweight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle Ear Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apthous Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Movement Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection Site Warmth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy To Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chlamydial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Coxsackie Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Mycotic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Blighted Ovum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Burnout Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pityriasis Rosea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

